The implications of colorectal cancer molecular biology in clinical practice

Surg Oncol Clin N Am. 2008 Apr;17(2):341-55, viii-ix. doi: 10.1016/j.soc.2007.12.005.

Abstract

Colorectal cancer (CRC) is the third most common malignancy in the United States. Advances in molecular biology have enhanced the understanding of colorectal carcinogenesis. Approximately 75% of CRCs are sporadic; the rest are hereditary or belong to a familial syndrome. Identification of familial forms of CRC have enabled the development of several models of carcinogenesis and made CRC a well-studied malignancy in terms of molecular pathogenesis. Pathways containing multiple mutations and genetic alterations that play a role in hereditary CRC pathogenesis have been elucidated. Many of the molecular changes seen in these pathways also are involved in the development of sporadic cancers.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cell Proliferation
  • Chemotherapy, Adjuvant
  • Chromosomal Instability
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / metabolism
  • Colorectal Neoplasms / pathology
  • Disease Progression
  • Humans
  • Mass Screening
  • Microsatellite Instability
  • Molecular Biology*
  • Neovascularization, Pathologic / genetics
  • Positron-Emission Tomography
  • Prognosis
  • Tomography, X-Ray Computed
  • Transforming Growth Factor beta / metabolism

Substances

  • Antineoplastic Agents
  • Transforming Growth Factor beta